Nebilet (Nebivolol)

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, reducing heart rate and contractility. It also stimulates endothelial nitric‑oxide release, causing peripheral vasodilation. The combination of β1‑blockade and nitric‑oxide mediated vessel relaxation leads to a net decrease in arterial pressure.

The appropriate dose of Nebilet is determined by the prescribing clinician based on the individual’s blood pressure, age, renal function and other medical factors. Physicians typically start with a low dose and may adjust it gradually to achieve target blood pressure, following local prescribing guidelines.

Safety data for nebivolol in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Nebilet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Nebilet (nebivolol) is a highly selective β1‑blocker that also enhances nitric‑oxide mediated vasodilation, a property not shared by many older beta‑blockers. This dual action can provide effective blood‑pressure control with a lower incidence of bronchospasm and metabolic side effects compared with non‑selective agents.

Nebilet should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and store them out of reach of children.

Nebilet is taken orally, usually once daily. It can be swallowed whole with or without food. Patients should follow the prescribing physician’s instructions and should not crush or chew the tablets unless specifically directed.

The most serious risks include severe bradycardia or heart block, marked hypotension, and acute bronchospasm, especially in patients with underlying respiratory disease. Any sudden dizziness, fainting, or difficulty breathing should prompt immediate medical evaluation.

Nebilet is contraindicated in patients with severe bradycardia, second‑ or third‑degree atrioventricular block, cardiogenic shock, or uncontrolled heart failure. It should also be avoided in individuals with a known hypersensitivity to nebivolol or any excipients in the tablet.